Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer

Table 1 Patients' characteristics

	Total	CTC positive	in %	Pvalue
Overall	245	122	50%
ER status	244	122	50	0.26
Negative	74	33	45
Positive	170	89	52
PR status	244	122	50	0.51
Negative	99	47	48
Positive	145	75	52
HER2 status	245	122	123	0.15
Negative¹	138	76	55
Positive²	75	31	41
Unknown³	32	15	47
Metastatic site	245	122	50	0.07
Visceral	96	39	41
Bone	35	14	40
Both	114	69	61
Extent of metastatic disease	245	122	50	0.03
One site	84	34	41
Multiple sites	161	88	55
Therapeutic setting	244	122	50
1st-line	94	48	51	0.48
2nd-line	64	28	44
3rd-line or more	86	46	54
CAIX	245 (253) ⁴	122	50
≤506 ng/ml	157 (163)	65	41	0.00
> 506 ng/ml	88 (90)	57	65
TIMP-1	245 (253) ⁴	122	50
≤454 ng/ml	179 (183)	77	43	0.00
> 454 ng/ml	66 (70)	45	68

¹ Immunohistochemistry score: 0/+1 or fluorescence in situ hybridization negative, ² ICH score: +3 or fluorescence in situ hybridization positive
³ not determined or ICH score +2 and fluorescence in situ hybridization not performed
⁴ in 9 patients CTC could not be determined
CAIX, carbonic anhydrase IX; CTC, circulating tumor cell; ER, estrogen receptor; HER, human epidermal growth factor receptor; PR, progesterone receptor; TIMP, tissue inhibitor of metalloproteinase.

ISSN: 1465-542X